12/1
07:44 am
nvcr
Novocure names Frank Leonard as CEO [Seeking Alpha]
Medium
Report
Novocure names Frank Leonard as CEO [Seeking Alpha]
12/1
07:00 am
nvcr
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
Medium
Report
Novocure Appoints Company President Frank Leonard as Chief Executive Officer
11/26
07:00 am
nvcr
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
Low
Report
Novocure to Participate in 37th Annual Piper Sandler Healthcare Conference
11/12
07:00 am
nvcr
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
Medium
Report
Novocure to Participate in 2025 Jefferies Global Healthcare Conference
10/30
12:40 pm
nvcr
NovoCure (NASDAQ:NVCR) had its price target raised by analysts at HC Wainwright from $38.00 to $42.00. They now have a "buy" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target raised by analysts at HC Wainwright from $38.00 to $42.00. They now have a "buy" rating on the stock.
10/30
07:00 am
nvcr
Novocure Reports Third Quarter 2025 Financial Results
Medium
Report
Novocure Reports Third Quarter 2025 Financial Results
10/27
10:55 am
nvcr
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $25.00 to $23.00. They now have a "neutral" rating on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at JPMorgan Chase & Co. from $25.00 to $23.00. They now have a "neutral" rating on the stock.
10/15
07:00 am
nvcr
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
Medium
Report
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
10/1
07:00 am
nvcr
Novocure to Report Third Quarter 2025 Financial Results
Medium
Report
Novocure to Report Third Quarter 2025 Financial Results
9/30
08:05 am
nvcr
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Low
Report
NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
9/29
04:30 pm
nvcr
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
Neutral
Report
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
9/15
07:00 am
nvcr
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
Low
Report
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)